Paul Barton Rodgers

Ithaka Life Sciences Ltd. provides advisory, guidance, and support for the life science industry. The British company was founded by Paul Barton Rodgers, who has been the CEO since incorporation.

ProteinLogic Ltd. has developed a diagnostic technology platform called immiprint®, which detects non-obvious diagnostic patterns in soluble immune proteins in the blood and other body fluids through machine learning. ProteinLogic is based in Cambridge, UK. These patterns form unique signatures of disease presence, stage, and potential response to treatment. The immiprint® technology has been clinically validated with the development of a signature in blood for the ruling out of active tuberculosis (TB), meeting the stringent criteria of the WHO for such a diagnostic test. The British company expects to create considerable additional value through the validation of other immiprint® signatures in its early stage development pipeline, with a focus on infectious, autoimmune, and inflammatory diseases.

Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom.

Ampika Ltd. discovers and develops drugs. It develops consumer products and prescription drugs from plant-based compounds. Its products includes cardiovascular protection, anti-infectives, diabetes, oncology, dermatological conditions and neurological. The company was founded by Francoise Barbira Freedman, Margaret Adey, Paul Rodgers and Jonathan Mark Treherne in May 2003 and is headquartered in Cambridge, the United Kingdom.

CYP Design Ltd. provides drug research and development services. It engages in the supporting drug research and development needs by offering stabilized, highly active cytochrome P450 (CYP) enzyme products. The firm also offers reliable contract research services in metabolism and toxicity testing and in bio catalysis. It has developed a generic expression system for the production of recombinant cytochrome P450 (CYP) in yeast, insect and mammalian cells. The company was founded by Bhabatosh Chaudhuri, Paul Barton Rodgers and William Primose in 2012 and is headquartered in Leicester, the United Kingdom.

Psynova Neurotech Ltd. provides commercial development and exploitation of novel biomarkers for Neuropsychiatric and other mental illnesses. The company was founded by Sabine Bahn on August 1, 2005 and is headquartered in Cambridge, the United Kingdom.